The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.
M. Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
T. J. Price
Consultant or Advisory Role - Amgen (U)
A. H. Strickland
Research Funding - Amgen
T. E. Ciuleanu
Honoraria - Amgen
W. Scheithauer
Consultant or Advisory Role - Amgen; Merck; Roche; Sandoz
Honoraria - Amgen; Bayer; Fresenius Biotech; Merck; Roche; Sandoz; Sanofi
S. O'Reilly
Research Funding - Amgen
M. M. Keane
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Amgen (U)
Y. Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Krishnan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen